AI in drug development: a multidisciplinary perspective
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The introduction of a new drug to the commercial market follows a complex and long process that typically spans over several years and entails large monetary costs due to a high attrition rate. Because of this, there is an urgent need to improve this process using innovative technologies such as artificial intelligence (AI). Different AI tools are being applied to support all four steps of the drug development process (basic research for drug discovery; pre-clinical phase; clinical phase; and postmarketing). Some of the main tasks where AI has proven useful include identifying molecular targets, searching for hit and lead compounds, synthesising drug-like compounds and predicting ADME-Tox. This review, on the one hand, brings in a mathematical vision of some of the key AI methods used in drug development closer to medicinal chemists and, on the other hand, brings the drug development process and the use of different models closer to mathematicians. Emphasis is placed on two aspects not mentioned in similar surveys, namely, Bayesian approaches and their applications to molecular modelling and the eventual final use of the methods to actually support decisions. Graphic abstract: Promoting a perfect synergy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ImageNet classification with deep convolutional neural networks
Krizhevsky, A., Sutskever, I., & Hinton, G. E. (2017) · Communications of the ACM · doi:10.1145/3065386 · Cited by 112,155
Hochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318 · cited 4×
“Since transformer-based models are more amenable to paralleli-sation, they have been trained over massive datasets in the NLP domain, leading to architectures such as Bidirectional Encoder Representations for Transformers (BERT) [48] or Fig.”
MethodInfluentialAdam: A Method for Stochastic Optimization
Kingma, D. P., & Ba, J. (2014) · arXiv · doi:10.48550/arxiv.1412.6980 · Cited by 98,946
Gradient-based learning applied to document recognition
Lecun, Y., Bottou, L., Bengio, Y., & Haffner, P. (1998) · Proceedings of the IEEE · doi:10.1109/5.726791 · Cited by 58,805
BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding
Devlin, J., Chang, M.-W., Lee, K., & Toutanova, K. (2019) · Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers) · doi:10.18653/v1/n19-1423 · Cited by 54,325
Learning representations by back-propagating errors
Rumelhart, D. E., Hinton, G. E., & Williams, R. J. (1986) · Nature · doi:10.1038/323533a0 · Cited by 31,892
Rudin, C. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0048-x · Cited by 10,561 · cited 1×
“One possibility is to use interpretable models, easily comprehensible for humans, as cogently argued by [162] who claims that in many contexts we may perform with such models almost as well as with deep ones.”
BackgroundUMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826
A Stochastic Approximation Method
Robbins, H., & Monro, S. (1951) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729586 · Cited by 9,643
Watkins, C. J. C. H., & Dayan, P. (1992) · Machine Learning · doi:10.1007/bf00992698 · Cited by 9,083
Cited by
Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Sánchez-Guirales, S. A., Simon, J. A., Tomietto, G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101328 · Cited by 488
The Integration of Artificial Intelligence into Clinical Practice
Karalis, V. D. (2024) · Applied Biosciences · doi:10.3390/applbiosci3010002 · Cited by 255
“The primary objective of reinforcement learning is to train autonomous agents to effectively make a series of decisions within a given environment, aiming to optimize the total cumulative reward obtained [29].”
BackgroundGanjavi, C., Eppler, M. B., Pekcan, A., Biedermann, B., Abreu, A., Collins, G. S., Gill, I. S., & Cacciamani, G. E. (2024) · BMJ · doi:10.1136/bmj-2023-077192 · Cited by 266
Generative machine learning for de novo drug discovery: A systematic review
Martinelli, D. D. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105403 · Cited by 177
Schleinitz, J., Langevin, M., Smail, Y., Wehnert, B., Grimaud, L., & Vuilleumier, R. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05302 · Cited by 88
Metadata
- Authors
- Gallego, V., Naveiro, R., Roca, C., Ríos Insua, D., & Campillo, N. E.
- Venue
- Molecular Diversity
- Published
- 2021-07-12
- Volume
- 25
- Issue
- 3
- Pages
- 1461-1479
- ISSN
- 1381-1991 (ISSN-L)
- 1573-501X
- OpenAlex
- W3183046872
- Cited by
- 73
- References
- 52
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AI in drug development: a multidisciplinary perspective. https://app.cochat.ai/papers/10.1007/s11030-021-10266-8
- The paper
- Gallego, V., Naveiro, R., Roca, C., Ríos Insua, D., & Campillo, N. E. (2021). AI in drug development: a multidisciplinary perspective. Molecular Diversity. https://doi.org/10.1007/s11030-021-10266-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.